within Pharmacolibrary.Drugs.ATC.R;

model R03CC11
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0017583333333333333,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0017,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03CC11</td></tr><td>route:</td><td>transdermal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tulobuterol is a long-acting beta2-adrenergic agonist used as a bronchodilator for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is most commonly administered via transdermal patches and is approved for clinical use in some countries, especially in Asia.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for typical adult population based on published summaries and indirect sources due to absence of direct dedicated PK studies in accessible literature. Most use is by transdermal patch.</p><h4>References</h4><ol><li><p>Kim, JH, et al., &amp; Seo, KW (2016). The pharmacokinetics of the β2-adrenoceptor agonist, tulobuterol, in Beagle dogs following transdermal and intravenous administration. <i>Veterinary journal (London, England : 1997)</i> 208 90–92. DOI:<a href=&quot;https://doi.org/10.1016/j.tvjl.2015.10.012&quot;>10.1016/j.tvjl.2015.10.012</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26639828/&quot;>https://pubmed.ncbi.nlm.nih.gov/26639828</a></p></li><li><p>Takizawa, Y, et al., &amp; Fukai, F (2017). Skin permeability of tulobuterol in two transdermal formulations and their followability. <i>Drug discoveries &amp; therapeutics</i> 11(5) 253–258. DOI:<a href=&quot;https://doi.org/10.5582/ddt.2017.01050&quot;>10.5582/ddt.2017.01050</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29021505/&quot;>https://pubmed.ncbi.nlm.nih.gov/29021505</a></p></li><li><p>Park, SI, &amp; Kim, BH (2018). Bioequivalence assessment of tulobuterol transdermal delivery system in healthy subjects . <i>International journal of clinical pharmacology and therapeutics</i> 56(8) 381–386. DOI:<a href=&quot;https://doi.org/10.5414/CP203268&quot;>10.5414/CP203268</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29932416/&quot;>https://pubmed.ncbi.nlm.nih.gov/29932416</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03CC11;
